Boudes Pol F 4
4 · Protalix BioTherapeutics, Inc. · Filed Sep 4, 2025
Insider Transaction Report
Form 4
Boudes Pol F
Director
Transactions
- Award
Common Stock
2025-09-03+7,500→ 7,500 total(indirect: By Trust) - Award
Stock Options (Right to Buy)
2025-09-03+15,000→ 15,000 totalExercise: $1.64Exp: 2035-09-03→ Common Stock (15,000 underlying)
Holdings
- 40
Commn Stock
Footnotes (4)
- [F1]Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant.
- [F2]To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee.
- [F3]The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.
- [F4]Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.